• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions

    4/4/24 9:30:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care
    Get the next $CODX alert in real time by email

    SALT LAKE CITY, April 4, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the Company naming David Nielsen to be its Chief Operations Officer (COO), Christopher Thurston as its Chief Technology Officer (CTO), and Seth Egan as Chief Commercialization Officer (CCO).

    (PRNewsfoto/Co-Diagnostics)

    • Prior to his new role at the Company, Richard Abbott (President) served as the President of Advanced Conceptions, Inc., a wholly-owned subsidiary of Co-Diagnostics since December 2021, and has been instrumental in establishing the teams and technology of the Co-Dx PCR platform*. His experience includes over 25 years in senior leadership positions of in-vitro diagnostics companies, including VP of Engineering at BioFire Diagnostics, where he built and led highly effective cross-functional teams that generated billions of dollars in revenue. Mr. Abbott holds a Master of Science degree from Brigham Young University and an M.B.A from the Wharton Business School. In his new role, Mr. Abbott will play a key role in the development and commercialization of the Co-Dx PCR platform and associated tests.
    • David Nielsen (COO) previously held the role of COO for Idaho Molecular, also acquired by Co-Dx in 2021, and has worked in concert with Advanced Conceptions and Co-Dx to help guide the development of the Company's new platform since that time. Including his time at Idaho Molecular, Mr. Nielsen has over 25 years of R&D technical and leadership experience, primarily at BioFire and BioFire Defense, filling various key roles which also included managing and coordinating the FilmArray diagnostic system throughout development and launch as the VP of Product Development. David earned both a Master of Science and M.B.A. from the University of Utah. As COO, David will leverage his experience to help lead Co-Dx's product development and manufacturing processes.
    • Christopher Thurston's (CTO) distinguished career has included decades of experience serving as senior developer and architect of software platforms for companies including Ernst and Young, BioFire Defense, and BioMerieux, demonstrating his expertise in big-data solutions. Following his experience in executive positions at several startups, Christopher co-invented the Co-Dx PCR platform at Idaho Molecular, pursuing his passion for democratizing access to PCR diagnostics though technological innovation. Mr. Thurston's technology expertise will be significant in the advancement of Co-Dx's platform and tests.
    • Seth Egan (CCO) has been with Co-Dx since its inception, leading the Company's sales, marketing and product commercialization efforts from the beginning, including managing the sales team as it sold approximately 35M Logix Smart® tests to centralized laboratories in more than 50 countries since the beginning of the pandemic. Mr. Egan has operated in many key capacities for the Company and continues to play an important role helping to oversee the relationship with CoSara Diagnostics, the Co-Dx joint venture in India. He holds a Bachelor of Science in Business Communications from Utah Valley University. Mr. Egan will play a crucial role as CCO in driving the Co-Dx PCR platform's commercialization efforts.

    Dwight Egan, Company CEO, remarked "I am enthused to have the honor of leading the team at Co-Dx with support from these accomplished individuals, whose background and experience are expected to be crucial additions to the management team as we proceed through our next stage of growth. We welcome them in their new roles as the world continues its shift towards a more decentralized approach to diagnostics. Co-Dx intends to help fill the equitable diagnostics access gap, which we believe can be made possible thanks to the efforts of people who share our corporate mission and possess the skills to make that vision a reality."

    *The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale. The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA.

    About Co-Diagnostics, Inc.:

    Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to locate genetic markers for use in applications other than infectious disease.

    Forward-Looking Statements:

    This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Forward-looking statements include statements made with respect to our Co-Dx PCR platform. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in our Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 14, 2024, and in our other filings with the SEC. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-appoints-new-president-and-other-c-level-positions-302108168.html

    SOURCE Co-Diagnostics

    Get the next $CODX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CODX

    DatePrice TargetRatingAnalyst
    8/12/2022$5.00Buy → Neutral
    Sidoti
    12/29/2021$14.00Buy
    Sidoti
    11/12/2021$16.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CODX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Egan Dwight H returned $12,407 worth of shares to the company (51,697 units at $0.24) and was granted 163,334 shares, increasing direct ownership by 21% to 634,494 units (SEC Form 4)

      4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

      5/27/25 4:09:40 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Brown Brian Lee was granted 134,166 shares and returned $11,559 worth of shares to the company (48,161 units at $0.24), increasing direct ownership by 20% to 505,911 units (SEC Form 4)

      4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

      5/27/25 4:09:30 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • President Abbott Richard David was granted 20,000 shares and returned $1,723 worth of shares to the company (7,180 units at $0.24), increasing direct ownership by 92% to 26,735 units (SEC Form 4)

      4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

      5/27/25 4:09:19 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care

    $CODX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Co-Diagnostics downgraded by Sidoti with a new price target

      Sidoti downgraded Co-Diagnostics from Buy to Neutral and set a new price target of $5.00

      8/12/22 9:07:51 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Sidoti initiated coverage on Co-Diagnostics with a new price target

      Sidoti initiated coverage of Co-Diagnostics with a rating of Buy and set a new price target of $14.00

      12/29/21 8:45:34 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. reiterated coverage on Co-Diagnostics with a new price target

      HC Wainwright & Co. reiterated coverage of Co-Diagnostics with a rating of Buy and set a new price target of $15.00 from $16.00 previously

      11/12/21 6:13:11 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care

    $CODX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Co-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference

      Salt Lake City, Utah, May 14, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that they will be participating in the D. Boral Capital ("DBC") Inaugural Global Conference on May 14, 2025 in New York City. The DBC conference connects emerging growth issuers across multiple sectors with institutional investors. Company representatives will be participating in one-on-one meetings to introduce institutions to the Company's value proposition and to the upcoming Co-Dx PCR* testing platform. More information about the conferen

      5/14/25 9:30:00 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results

      SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Results:  ●Revenue of $0.1 million, which declined from $0.5 million during the Q1 2024 primarily due to timing of grant revenue recognition. The Company did not recognize any grant revenue during the first quarter 2025    ●Operating expenses of $8.6 million decreased by 18.2% from the prior year first quarter    ●Operating loss of $8.6 million compared to operating loss of $10.3 million in Q

      5/8/25 4:01:00 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast

      SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations. The conference call and webcast will be available via: Webcast: ir.codiagn

      4/29/25 7:30:00 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care

    $CODX
    Leadership Updates

    Live Leadership Updates

    See more

    $CODX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CODX
    Financials

    Live finance-specific insights

    See more

    $CODX
    SEC Filings

    See more
    • Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions

      SALT LAKE CITY, April 4, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the Company naming David Nielsen to be its Chief Operations Officer (COO), Christopher Thurston as its Chief Technology Officer (CTO), and Seth Egan as Chief Commercialization Officer (CCO). Prior to his new role at the Com

      4/4/24 9:30:00 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics, Inc. Appoints Chief Regulatory Affairs Officer

      SALT LAKE CITY, Aug. 29, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Ivory Chang as the Company's Chief Regulatory Affairs Officer. Ms. Chang's in-depth regulatory affairs experience has included time spent with several notable names in the diagnostics industry, including Roche, Boston Scientific, BD Biosciences, Cepheid, Thermo Fisher Scientific, and more. Her background has i

      8/29/23 9:30:00 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer

      SALT LAKE CITY, Nov. 1, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Mark Poritz, PhD as the Company's new Chief Scientific Officer ("CSO"). Dr. Poritz is a Harvard University and UC San Francisco educated molecular biologist with more than 30 years of experience in the application of PCR and related methods to gene cloning, drug discovery, infectious disease diagnostics and aptamer selection, who has also served as a reviewer for more than 30 different NIH/NIAID study sections focusing on inf

      11/1/22 9:32:00 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Co-Diagnostics Inc. (Amendment)

      SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

      2/13/24 5:02:32 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Co-Diagnostics Inc. (Amendment)

      SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

      2/9/22 3:43:31 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Co-Diagnostics, Inc. (Amendment)

      SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

      7/12/21 8:29:19 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results

      SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Results:  ●Revenue of $0.1 million, which declined from $0.5 million during the Q1 2024 primarily due to timing of grant revenue recognition. The Company did not recognize any grant revenue during the first quarter 2025    ●Operating expenses of $8.6 million decreased by 18.2% from the prior year first quarter    ●Operating loss of $8.6 million compared to operating loss of $10.3 million in Q

      5/8/25 4:01:00 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast

      SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations. The conference call and webcast will be available via: Webcast: ir.codiagn

      4/29/25 7:30:00 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results

      SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 Financial Results: Revenue of $3.9 million, which declined from $6.8 million during the prior year primarily due to higher Grant revenue in 2023. Grant revenue totaled $3.1 million while product revenue totaled $0.8 millionOperating expenses of $43.0 million decreased by 5

      3/27/25 4:01:00 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Co-Diagnostics, Inc. (0001692415) (Filer)

      5/29/25 4:30:38 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Co-Diagnostics Inc.

      10-Q - Co-Diagnostics, Inc. (0001692415) (Filer)

      5/8/25 4:10:37 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Co-Diagnostics, Inc. (0001692415) (Filer)

      5/8/25 4:05:13 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care